In 2014, she joined HUB as one of the founding scientists and worked as a Group Leader for the cystic fibrosis and pancreatic cancer organoid programs. In 2016, she was appointed Scientific Director at HUB and in her new role she was responsible for leading both the contract service and research programs. Under Sylvia?s leadership the Organoid Technology evolved from a highly innovative basic research tool to a industry leading drug development platform. Since 2020 she holds the position of Chief Scientific Officer.